Notably, the ROC analysis using the same datasets indicated FGD3 is a strong predictive biomarker tightly correlated with increased relapse-free survival in breast cancer patients (FGD3 area under curve: AUC >0.7; Fig. 7J, K; AUC >0.7, strong biomarker; AUC >0.6, moderate biomarker; AUC < 0.6, weak, or not significant, biomarker; [64]). Here, FGD3 is linked to breast carcinoma.